AllQuantitative Report
Argus•June 09, 2021
Argus•June 09, 2021PCRX: Lowering target price to $64.00
Summary
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Analyst Report: Merck & Co., Inc.Apr 25, 2024 •
MRK
- Analyst Report: Bristol-Myers Squibb CompanyApr 25, 2024 •
BMY
- Daily – Vickers Top Buyers & Sellers for 04/25/2024Apr 25, 2024 •
KMB, WABC, NTIC, CTBI, KR, ZWS, RXO, NWFL, DAL, CRM
- AMPH: What does Argus have to say about AMPH?Apr 24, 2024 •
AMPH
- CORT: Lowering target price to $18.00Apr 24, 2024 •
CORT